Zarah
Product Images NDC 53002-1627

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zarah (NDC 53002-1627). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021627)

Label for Zarah tablets 28 day regimen by RPK Pharmaceuticals, Inc. The image shows directions to take one tablet daily as directed, prescription-only status, barcode, lot number, and important usage information. The package contains 28 tablets and emphasizes proper dispensing and storage instructions.*

FDA Label Image

Figure 1 (Zarah 01)

A forest plot displaying hazard ratios and odds ratios from various studies including Ingenix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD. The chart categorizes studies into prospective cohort, case-cohort, and non-fatal idiopathic cases, showing point estimates with confidence intervals on a logarithmic scale ranging from 0.1 to 5.*

FDA Label Image

Figure 2 (Zarah 02)

A horizontal bar chart illustrating the number of women with a blood clot per 10,000 women years (WY) across different groups: Non-Pregnant Non-COC users (1 to 5), COC users (3 to 9), Pregnant women (5 to 20), and Postpartum women (12 weeks after delivery) with the highest range (40 to 65).*

FDA Label Image

Image (Zarah 03)

Chemical structure diagrams of two active ingredients: Drospirenone and Ethinyl estradiol, showing their steroidal molecular frameworks as associated with the pharmaceutical product Zarah from RPK Pharmaceuticals, Inc.*

FDA Label Image

Image (Zarah 04)

An illustration depicting contraceptive methods effectiveness ranked by pregnancy rates per 100 women per year. The diagram uses an arrow pointing from fewer to more pregnancies, grouping methods into categories: implants, injections, intrauterine devices, and sterilization at the highest effectiveness; birth control pills, skin patch, and vaginal ring with hormones in a moderate effectiveness group; condoms and diaphragm with lower effectiveness; and no sex during fertile days, spermicide, withdrawal, and no birth control with highest pregnancy rates.*

FDA Label Image

Image (Zarah 05)

Zarah oral contraceptive blister pack label showing a 28-day pill calendar with daily tablet placements labeled by days of the week and the acronym K E E W. The label includes instructions to start on Sunday and follow arrows, place the enclosed day label, and store at controlled room temperature. Active ingredients listed are Drospirenone and Ethinyl Estradiol, USP 3 mg/0.03 mg. The labeler is RPK Pharmaceuticals, Inc.*

FDA Label Image

Image (Zarah 06)

A horizontal bar chart showing the number of women with a blood clot out of 10,000 woman years (WY) for different groups: Non-Pregnant Non-COC user (range 1 to 5), COC-User (range 3 to 9), Pregnancy (range 5 to 20), and Postpartum (12 weeks only) with a higher range from 40 to 65. The chart highlights increased blood clot risk in postpartum women compared to other groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.